This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Innovative drugs promote precision cancer therapy
Clinical Cancer Bulletin Open Access 06 December 2023
-
Recent advances in targeted strategies for triple-negative breast cancer
Journal of Hematology & Oncology Open Access 28 August 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2203690 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. T-DXd active in HER2-low disease. Nat Rev Clin Oncol 19, 493 (2022). https://doi.org/10.1038/s41571-022-00663-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-022-00663-9
This article is cited by
-
Recent advances in targeted strategies for triple-negative breast cancer
Journal of Hematology & Oncology (2023)
-
Innovative drugs promote precision cancer therapy
Clinical Cancer Bulletin (2023)